e-Therapeutics plc Release: Appointment Of Non-Executive Chairman
6 January 2016: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce the appointment of Iain Ross to the Board of Directors as Non-Executive Chairman.
Iain Ross will join the Company on 6 January 2016. At this time, Professor Malcolm Young will step down as acting Chairman and continue his role as Chief Executive Officer.
Iain Ross has over 35 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions. He has spent more than 25 years in cross-border management as a Chairman and CEO. Iain has led and participated in five Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim.
He is currently Non-Executive Chairman of Premier Veterinary Group plc, Non-Executive Chairman of Biomer Technology Ltd and a Non-Executive Director of Anatara LifeSciences Ltd, Benitec Biopharma Ltd. and Novogen Ltd. He is a qualified Chartered Director, and Vice Chairman of the Council of Royal Holloway, London University.
Previously, Iain held significant roles in multi-national companies including Sandoz, Hoffman La Roche and Celltech Group plc where as Chief Executive Officer of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit. As Chairman and Chief Executive Officer at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics plc (formerly SR Pharma plc), Iain turned the business around through M&A and establishing collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc.
Commenting on the appointment, Professor Malcolm Young, CEO of e-Therapeutics, said: “We welcome Iain to the Board at e-Therapeutics. His extensive experience further strengthens the Company and will be invaluable as we move towards realising the potential of our discovery and development programmes.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Iain Gladstone Ross, aged 61 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships:
Anatara Lifesciences Ltd (ASX)
Benitec Biopharma Ltd (ASX/NASDAQ)
Biomer Technology Ltd
Gladstone Consultancy Partnership
Gladstone Partners Limited
Novogen Limited (ASX/NASDAQ)
Pharminox Limited
Premier Veterinary Group plc (LSE: Main Market)
Rosscard Limited
Tacere Therapeutics Inc
Yellowcross Limited
Directorships held in the last five years:
Amarantus Bioscience Holdings Inc. (NASDAQ:OTC)
Breast Cancer Haven
Coms plc (LSE: AIM)
Powerstax Limited
Tissue Therapies Europe Limited
Trading Haven Limited
Iain Ross holds no ordinary shares in the Company.
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Iain Ross will join the Company on 6 January 2016. At this time, Professor Malcolm Young will step down as acting Chairman and continue his role as Chief Executive Officer.
Iain Ross has over 35 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions. He has spent more than 25 years in cross-border management as a Chairman and CEO. Iain has led and participated in five Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim.
He is currently Non-Executive Chairman of Premier Veterinary Group plc, Non-Executive Chairman of Biomer Technology Ltd and a Non-Executive Director of Anatara LifeSciences Ltd, Benitec Biopharma Ltd. and Novogen Ltd. He is a qualified Chartered Director, and Vice Chairman of the Council of Royal Holloway, London University.
Previously, Iain held significant roles in multi-national companies including Sandoz, Hoffman La Roche and Celltech Group plc where as Chief Executive Officer of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit. As Chairman and Chief Executive Officer at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics plc (formerly SR Pharma plc), Iain turned the business around through M&A and establishing collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc.
Commenting on the appointment, Professor Malcolm Young, CEO of e-Therapeutics, said: “We welcome Iain to the Board at e-Therapeutics. His extensive experience further strengthens the Company and will be invaluable as we move towards realising the potential of our discovery and development programmes.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Iain Gladstone Ross, aged 61 years, has been a director of the following companies during the five years preceding the date of this announcement:
Current directorships:
Anatara Lifesciences Ltd (ASX)
Benitec Biopharma Ltd (ASX/NASDAQ)
Biomer Technology Ltd
Gladstone Consultancy Partnership
Gladstone Partners Limited
Novogen Limited (ASX/NASDAQ)
Pharminox Limited
Premier Veterinary Group plc (LSE: Main Market)
Rosscard Limited
Tacere Therapeutics Inc
Yellowcross Limited
Directorships held in the last five years:
Amarantus Bioscience Holdings Inc. (NASDAQ:OTC)
Breast Cancer Haven
Coms plc (LSE: AIM)
Powerstax Limited
Tissue Therapies Europe Limited
Trading Haven Limited
Iain Ross holds no ordinary shares in the Company.
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.